Samsung Biologics Sees Biosimilars As One Of Three Key Pillars
Follows Deal To Take Full Ownership Of Samsung Bioepis From Biogen
CDMO, biosimilars and new drugs are the three key business areas for Samsung Biologics • Source: Arturas Jasevicius / Alamy Stock Photo 
